Wire flash
FinanceBoston Scientific announces global restructuring, expects headcount reductions and ~$500M annual pre-tax savings
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
Boston Scientific announced a global restructuring program on July 21, 2026, aimed at driving sustained cost efficiencies and supporting growth. The plan, disclosed in an SEC filing on July 27, includes supply chain optimization, production line transfers, and functional transformation, expected to be largely completed by the end of 2029. The medtech giant estimates the restructuring will cost between $700 million and $800 million, with $600-700 million in future cash outlays, and is expected to reduce annual pre-tax expenses by approximately $500 million. While new jobs will be created, the company expects headcount reductions, with up to $300 million allocated for terminations. Boston Scientific's stock rose 2.85% to $45.51 on the NYSE following the announcement. The company is set to release its Q2 results on July 29, after trimming its full-year outlook by 2% at the top end due to competitive dynamics.
Source report
Author: Ross Law Source: Medical Device Network
Boston Scientific is launching a global restructuring program aimed at driving "sustained cost efficiencies" and supporting continued growth, a move the company acknowledges will result in job cuts across the business.
Restructuring Plan Details
The 2026 restructuring plan includes:
- Supply chain optimization, including transferring certain production lines among facilities
- Targeted functional transformation
- Organizational "structure evolution" to drive sustained cost efficiencies
These activities are expected to be largely completed by the end of 2029.
Financial Impact
The plan, approved by Boston Scientific's board on July 21 and disclosed in a Form 8-K filing with the U.S. Securities and Exchange Commission (SEC) on July 27, is expected to cost between $700 million and $800 million. Of this total:
- Approximately $600 million to $700 million is expected to result in future cash outlays
- Annual pre-tax expenses are projected to decrease by approximately $500 million as the program's benefits are realized
Stock Performance
Boston Scientific's shares on the New York Stock Exchange (NYSE) rose 2.85% to $45.51 at market close on July 27, up from $44.60 at market open. The company has a market capitalization of $67.64 billion. Shares rose an additional 2% at market open on July 28.
Headcount and Cost Breakdown
While Boston Scientific noted that the plan will create new jobs to support its portfolio and global market needs, it also expects "some" headcount reductions as a result of the restructuring. No specific numbers were provided, but the company's Form 8-K cost breakdown estimates:
- Up to $300 million will be incurred due to terminations
- Up to $350 million will relate to transferring product manufacturing lines between geographically dispersed facilities
- Up to $150 million for other costs associated with the plan's completion
Upcoming Results
Boston Scientific is scheduled to release its Q2 results on July 29. In Q1, the company reported revenue of approximately $5.2 billion, broadly in line with the same quarter in 2025. However, the company trimmed its full-year outlook by 2% at the top end, with CEO Mike Mahoney citing "ongoing competitive dynamics."
This article was originally created and published by Medical Device Network, a GlobalData owned brand.
Source
Yahoo FinanceWestern
Part of this Story
Boston Scientific Announces Global Restructuring, Q2 Results Beat Estimates